Make the Case for Discovery & Development Europe

The Discovery & Development Top 25 of ’25 eBook brings together the most impactful voices, technologies and ideas shaping early-stage drug discovery, formulation and delivery today.

You want to attend Discovery and Development Europe 2026. Your guest pass costs nothing. The question your manager is likely to ask is whether two days away from your current work is worth it.

The answer is yes, and the arguments below will help you make that case. We have also written eight ready-to-use letter templates, one for each major programme area across Drug Discovery Europe and Formulation and Delivery Europe, so you can send something specific and credible rather than a generic conference request.

Panel Discussion: Technological Advancements For Novel Target Discovery

Application of new technologies in identifying therapeutics for novel or currently undruggable targets
Utilising AI/ML
Challenges & future opportunities

Panellists include Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech, Ian Roberts, Senior Director, Digital Biology, Healx & Zoran Rankovic, Director, Center for Protein Degradation, The Institute of Cancer Research

Panel Discussion: Novel Platforms & Techniques To Improve Hit Identification

• Optimising Hit discovery
• Minimising false positives
• Integration of techniques

Moderated by Jonathan Hopper, Vice President Platforms & Founder, OMass Therapeutics

Panel Discussion: Fostering Partnerships & Collaboration In 2025 – as part of our newly introduced Early-Stage R&D Innovation Programme

Emerging technologies & techniques
Cross-sector partnership
Open innovation

Moderated by Alexander Natz, Secretary General, EUCOPE & panellists from Cicio Holdings, BioAge Labs, European Commission, Pfizer & Business Region Gothenburg

Panel Discussion: Breakthrough Biotech: How Research Leaders Fund The Next Big Idea

How research leaders identify and support fundable biotech innovations
Overcoming early-stage funding gaps in biotech startups
The role of research partnerships with pharma, VCs, and industry in startup success
What startups can learn from research-backed biotech wins

Panellists include Christoph Rösli, Director of Research Bern, CSL Behring & Member of the Selection Board, BaseLaunch; David Jenkinson, Head of Childhood Cancer Translational Challenge, LifeArc; David Dexter, Director of Research, Parkinsons UK

Fireside Chat: Impact of AI & Big Data in Drug Discovery & Development

Panel Discussion: Translational Studies to Support Better Drug Design

Bridging the gap between pre-clinical & clinical research
Biomarkers & AI/ML in translational research

Moderated by Philippe Marc, Executive Director, Global Head of Integrated Data Sciences, Novartis

Panel Discussion: Fostering Collaboration To Accelerate Neurodegenerative Disease Research

• Pharma, biotech & academic partnerships
• The need for innovation, data & technology in CNS research
• Challenges to be solved through collaboration

Moderated by Emma Mead, Chief Scientific Officer, Alzheimer’s Research UK Oxford Drug Discovery Institute, University of Oxford. Panellists include Knut Biber, Research Fellow & Head of Glial Biology Team, AbbVie; Sarah Jolly, Principal Scientist, LifeArc; Michael Johnson, Professor of Neurology & Genomic Medicine, Imperial College London

Day 2 Breakfast Workshop - LifeArc: Biomarkers In Neurodegenerative Diseases: From Detection To Progression - Are Blood -Based Biomarkers Enough?

Beyond blood-based biomarkers?
Are we any closer to a solution?
Application of AI/ML

Moderated by Manuela Cerina, Scientific Director – Neurodegeneration, LifeArc

Panel Discussion:
Automation & Robotics In Drug Discovery & Development – Where Are We Now?

• Impact of automation
• AI/ML
• Robotics in lab processes

Moderated by Rekha Lakshmanan, Global Head of Data Office, AstraZeneca

Panellists include: James Love, Vice President Cross Modalities Workflows, Novo Nordisk, Sarah Trice, COO & Head of US Operations, XtalPi & Tom Kissling, pRED Lab Automation Partner, Roche

Day 2 Breakfast Workshop: SiLA & AnIML Splash

• Splash! Is a unique event for every digital lab enthusiast. It combines an educational part with a hands-on session to try out standards in action. Pick up the details on the popular SiLA and AnIML standards, understand how they work and where you can put them to use. Our hands-on session lets you experience the standards in action firsthand. We’re bringing real and cloud-based instruments and lots of example data sets
• Feel free to bring an instrument or your own data

Panel Discussion: Moving Beyond Oral Delivery

• Nanoparticles
• Inhalation
• Transdermal
• Developments with Oral Delivery

Moderated by Sandor Batkai, Life Science Consultant, Former, Head of Medical Research and Intelligence, Cardior Pharmaceuticals

Panellists include Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group, Joël Richard, Executive Head, Product Development, DBV, Kamalinder Singh, Professor of Pharmaceutical, Technology & Drug Delivery, Karsten Mäder, Professor, Martin Luter University Halle-Wittenberg

Panel Discussion: AI/ML & Novel Technologies In Formulation & Delivery

Applications of AI/ML in formulation and delivery
AI-driven approaches to optimise dosage forms
Novel delivery technologies
AI/ML for personalised formulations

Moderated by Shilpa Thosar, CMC/Regulatory CMC Executive, Former Executive Director, Cara Therapeutics

Roundtable: Discovery And Delivery Of Therapeutics Across The Blood Brain Barrier – Where Are We Now?

Brain shuttle platform
Monocytes
Microbubbles

Moderated by Shadi Farhangrazi, Chief Executive Officer, S.M. Discovery Group

Meet Our Expert Speakers

Discovery & Development Europe 2025 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Andreas Gryczke

ACoS Research Fellow,

AbbVie

Emma Mead

CSO,

ARUK Oxford Drug Discovery Institute

Heinrich Haas

Chief Technology Officer,

Neovacs

Karin Conde-Knape

Senior Vice President, Early Development,

Novo Nordisk

Morten Grunnet

Vice President, Head of Neuroscience ,

Lundbeck

Philippe Marc

Executive Director, Global Head of Integrated Data Sciences,

Novartis

Shadi Farhangrazi

CEO,

S. M. Discovery Group (SMDG)

Sorina Morar-Mitrica

Director Science & Technology,

Novartis

Stephen Pham

Senior Vice President, Product Development,

Avalyn Pharma Inc.

Ulrich Betz

Senior Vice President Innovation,

Merck

Show More Speakers

Hide Speakers

Roderick Beijersbergen

Head,

nki

Christoph Rösli

Director Research,

CSL Behring & BaseLaunch

Amal Ali Elkordy

Professor of Pharmaceutics,

University of Sunderland

Jack Doolan

Principal Scientist,

GSK

Christine Maurer

Scientific Associate Director Biotransformation,

Merck Healthcare KGaA

Miroslav Cik

Senior Principal Research Scientist,

Abbvie

Markus Hierl

Principal Associate,

Hoffmann La Roche Ltd

Juan-Carlos Sanchez

Partner,

Woxsen University

Aaron Smith

Associate Director,

AstraZeneca

Abhishek Choudhary

Principal Data Engineer,

Bayer

Abi Heath

Patent Attorney & Counsel,

Kilburn & Strode

Alain Martelli

External Science Lead Europe, Discovery Network,

Pfizer

Alex Alderton

Senior Director,

Astrazeneca

Amardeep Singh Bhalla

Executive Director,

Regeneron

Andreas Bernkop-Schnürch

Professor,

Innsbruck University

Andrew Woodhead

Head of Chemistry,

Astex Pharmaceuticals

Andy Pike

DMPK Project Lead,

AstraZeneca

Antonia Stepan

Section Head, Medicinal Chemistry,

Roche

April Woulfe

Senior Scientist,

Alchemab Therapeutics Ltd.

Arianna Sabò

Head of R&D,

QUANTRO Therapeutics GmbH

Arne Skerra

Professor ,

Technische Universität München

Benedict Cross

CTO,

PhoreMost Ltd

Burkhard Schäfer

Managing Director & Director at SiLA,

SiLA

Cesare Spadoni

Co-Founder & Chief Operating Officer,

Oncoheroes Biosciences

Chuang Kee Ong

Director Data Product,

GSK

Cornelis Van Tilburg

Head of KiTZ CTU,

Hopp-Kindertumorzentrum Heidelberg

Covadonga Paneda

Chief Operating Officer,

Altamira Therapeutics

Daniel Tondera

Head of Biology,

Pantherna Therapeutics

David Dexter

Research Director,

Parkinson's UK

David Gnutt

Vice President, Complex In Vitro Lead, RED Cardiovascular, Renal and Immunology, ,

Bayer

David Jenkinson

Head of Childhood Cancer Translational Challenge,

LifeArc

Delphine Heenen

Kicker in Chief Managing Director,

KickCancer

Diana Knapp-Bühle

Associate Director and DMPK Lead,

Merck Healthcare KGaA

Eric Lorent

Senior Scientist,

Sanofi

Eva Aparicio

Product Owner,

Roche

Fabrizio Dissegna

Formulator,

Chiesi

Farshad Ramazani

Functional Lead biologic drug development,

Novartis

Florian Ries

Senior Scientist,

AbbVie

Gergely Toth

Chief Executive & Scientific Officer, Founder,

Cantabio Pharmaceuticals

Giovanni Spagnolli

Chief Technology Officer,

Sibylla Biotech

Guillaume Alonso

Marketing,

Oxford Global

Heena Khatter

Principal Scientist,

Roche

Ian Roberts

Senior Director, Digital Biology,

Healx

Iris Valtingojer

Sanofi Childhood Cancer R&D CSR Lead,

Sanofi

James Connell

Scientific Director - Translational Matrix Group,

LifeArc

James Love

Vice President, Cross Modalities Workflows,

Novo Nordisk

Jens Frauenfeld

Chief Executive Officer,

Salipro Biotech

Jens Twellmeyer

Associate Director Science & Technology,

Novartis

Joao Seixas

CEO,

TargTex S.A.

Johanna Roostalu

Director, Therapeutics, Venture Creation,

BioInnovation Institute

Jonathan Hopper

Vice President, Platforms and Founder,

OMass Therapeutics

Jörg Berghausen

Associate Director,

Novartis

Jose-Carlos Gomez-Tamayo

Senior Scientist II,

Janssen Pharmaceutical Companies of Johnson & Johnson

Kamalinder Singh

Professor of Pharmaceutical Technology & Drug Delivery,

University of Central Lancashire

Karsten Maeder

Professor,

Martin Luther University Halle-Wittenberg

Katja Petkau Milroy

Formulation Scientist,

Microsol

Kelly Zalocusky

Senior Director of Computational Biology, Neuroscience ,

Recursion Pharmaceuticals

Knut Biber

Research Fellow & Head of Glial Biology Team,

AbbVie

Konstantinos Gkatzis

Ceo ,

Epiceller

Kristina Levan

Business Developer,

Business Region Gothenburg

Krisztian Kaszas

Principal Scientist,

Johnson & Johnson

Lars van der Veen

Chief Scientific Officer,

ionctura

Laura Gasparini

Director -Tau pathobiology,

AbbVie

Lene Gerlach

Venture Partner; Founder & Chairperson,

Hadean Ventures; Women in Life Science Denmark

Maeve Caldwell

Professor in Neuroscience, Physiology,

Trinity College Dublin

Manuela Cerina

Scientific Director of Neurodegeneration,

LifeArc

Marcos Costa

Principal Scientist,

Roche

Maria Levitin

Director of RNA Oligonucleotide Delivery, Genetic Medicine,

Grünenthal GmbH

Marie-Christine Pardon

Assistant Professor in Translational Neuroscience,

University of Nottingham

Marius Lutz

Scientist, Process Chemistry,

Hoffmann La Roche Ltd

Mark L. Mark L.

president,

Tavotek Biotherapeutics

Martinus Capelle

Distinguished Scientist II,

Erasmus MC

Meike Harms

Lead Scientist,

Merck

Meiling Li

Principal Scientist,

Roche

Michael Johnson

Professor of Neurology & Genomic Medicine,

Imperial College London

Moein Moghimi

Professor of Nanomedicine and Pharmaceutics,

Newcastle University

Naisha Shah

Vice President of Data Science,

BioAge Labs

Peng Leong

CBO and Head of Brain Aging,

Bioage labs

Phil Noble

Head of Single B Cell Antibody Discovery,

UCB Pharma

Philip Hewitt

Global Head of Early Investigative Toxicology,

Merck

Rainer Wilcken

Senior Director, Computational Chemistry,

Flare Therapeutics Inc

Rajiv Nayar

President,

HTD Biosystems Inc

Rick Ewing

VP, Head of Chemistry,

Rapafusyn

Sabine Kuratli

CMC Lead,

CEPI

Sagar Chandekar

Senior Medical Director, Alzheimer's Disease,

Novo Nordisk

Sam Daems

Researcher, I3h (ULB) & Portfolio Principal,

Waterland Private Equity

Sandor Batkai

Freelance Consultant,

Cardior Pharmaceuticals

Sarah Jolly

Principal Scientist,

LifeArc

Simone Hornemann

Director UZH CRISPR Screening Hub,

University of Zurich

Sophie Janbon

Director,

AstraZeneca

Steen Krogsgaard

Scientific Automation Director,

Novo Nordisk

Stefan Schiesser

Director of Medicinal Chemistry,

AstraZeneca

Stefano Romanelli

Senior Government Affairs Manager,

EUCOPE

Stephanie Harlfinger

Senior Director, Global Head NCE DMPK,

Merck & Cie KmG

Supriyadi Hafiz

Senior Scientist,

Merck Healthcare KGaA

Suruchi Vishwasrao

Sr scientist,

Merck Life Science Pvt. Ltd.

Sven Verguts

Associate Director, Emerging Biotech & ATMPs,

Merck

Tamara Maes

Former Chief Scientific Officer & Founder,

Oryzon Genomics

Tanvir Tabish

Director, Early Formulation Development,

AstraZeneca

Thanneer Malai Perumal

Senior Principal Scientist,

Hoffmann La Roche Ltd

Tjasa Vrlinic

Principal Investigator,

Medincell

Tom Kissling

pRED Automation Partner & Director at SiLA,

F. Hoffmann-La Roche AG

Tomasz Ratajczak

Formulation Expert,

Polpharma

Toria Legh-Land

Modelling Lead,

Microsol

Trond Ulven

Professor,

Copenhagen University

Valentina Romeo

Principal Scientist & Group Leader,

Roche

Vik Reebye

Head of Academic Partnerships ,

MiNA Therapeutics Ltd

Virginia Ballotta

New Ventures Manager,

BaseLaunch

Vladimir Talibov

Associate Principal Scientist,

Sprint Bioscience

Xavier Garrabou

Director of Operations,

Vivtex

Yi Sun

Associate Professor,

Technical University of Denmark

Zeeshan Ahmad

Reader in Pharmaceutics and Drug Delivery,

University of Manchester

Zhi Yao

Principal Scientist,

LifeArc

Zhizhou Fang

Associate Scientific Director,

Merck Healthcare KGaA

Zoran Rankovic

Professor of Chemical Biology & Director, Centre for Protein Degradation,

St. Jude Children's Research Hospital, Department of Chemical Biology & Therapeutics, Memphis

Proteins, Antibodies & ADCs
Panel Discussion: What Is The Next Game Changer In Antibody Engineering?

Moderator: Karen Silence, Head Preclinical Product Development, ArgenX
Panellists include Berit Olsen Krogh, Senior Research Fellow; and Lundbeck Andrew Buchanan, Principal Scientist, AstraZeneca

Peptides
Roundtable: Regulatory Insights On Bringing A Peptide To Human Trials

Moderator: Paul Reid, Co-Founder & Chief Scientific Officer, Celtic Bio

Oligonucleotides
Workshop: Development Of Targeted Delivery Systems

Two Presentations, followed by a Panel Discussion on 'The Next Chapter Of Oligonucleotide Delivery'
Moderator: Steve Hood, Senior Director, Oligonucleotide ADME Strategy, GSK

Sustainability in Tides & Biologics
Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

Moderator: Walter Cabri, Full Professor of Organic Chemistry, University of Bologna
Panellists include Daniel Sejer Pedersen, Chemical Development Specialist CMC API Development, Novo Nordisk;
Anna Maria Papini, Full Professor & Group Leader, University of Florence;
Louis Diorazio, Senior Principal Scientist, New Modalities, AstraZeneca;
Alessandra Tolomelli, Associate Professor, University of Bologna

Immunotherapy & Immuno-oncology
Presentation: How The RNA Technologies Could Help To Prevent Infectious Diseases And Could Be Applied To Various Chronic Disease Immunotherapies?

Presented by: Daniel Larocque, Innovation Lead, Innovation and Emerging Science, Sanofi

Anna Perdrix

co-CEO,

Sixfold Bioscience

Fernando Albericio

Research Professor,

University of KwaZulu-Natal

Kelly Loyet

Distinguished Scientist,

Genentech

Kevin Fitzgerald

Chief Scientific Officer,

Epsilogen

Livija Deban

Chief Scientific Officer,

Prokarium

Maria Koufali

Director,

UK Vaccine Innovation Pathway

Marta Amaral

Head High Throughput Protein Engineering in Large Molecules Research,

Sanofi

Nazneen Dewji

Chief Executive Officer,

Cenna Biosciences Inc.

Philip Beer

Chief Scientific Officer,

Step Pharma

Rick Hibbert

Vice President & Head of CMC Science & Technologies,

Genmab

Sudhir Agrawal

Founder,

Arnay Sciences

Tristan Vaughan

Vice President Protein Engineering,

Immunocore

Sandor Batkai

Freelance Consultant,

Cardior Pharmaceuticals

Kerry Chester

Professor of Molecular Medicine, Research Department of Oncology - University College London, Director at The Antibody Society,

The Antibody Society

Dorothy Bray

Senior Executive,

Celtic Biotech

Aaron John Balana

Scientist III,

Genentech

Aikaterini Gatsiou

Assistant Professor,

Lancaster University

Alain Wagner

Research Director,

Strasbourg University

Alastair Lawson

Fellow,

UCB

alessandra tolomelli

professor,

university of Bologna

Alessandro Gori

Group Leader,

National Research Council of Italy

Alexandria Cogdill

Head of Strategic Initiatives, Global Business Development,

Daiichi Sankyo, Inc

Álvaro Enríquez García

Medicinal Chemist,

Eli Lilly

Amita Vaidya

Principal Scientist,

Sanofi

Ammar Ahmed

Senior Scientist,

Imperial College London

Amy Li

Director, Drug Discovery,

T-Therapeutics Ltd

Anand Kumar

Senior Scientist,

Sanofi

Andreas Midbøe Hoff

Head of In Silico & AI Department,

Nykode

Andreas Reichel

Vice President, Head of Research Pharmacokinetics,

Bayer

Andrew Buchanan

Scientist,

AstraZeneca

Andrew Creese

Associate Director,

Immunocore

Andrew Jamieson

Professor Of Chemical Biology ,

University of Glasgow

Andrew Slee

Chief Operating Officer,

AgenusBio

Andri Vasou

Head of Platform Development,

Bioarchitech

Aneesh Karatt Vellatt

Chief Scientific Officer,

Maxion Therapeutics

Anna Hine

Professor of Protein Engineering,

Aston University

Anna Maria Papini

Professor, Interdepartmental Research Unit of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff",

University of Florence

Annelise Vuidepot, PhD

SVP CTO - Head of Pipeline & Platform Research and UK site Head,

Immunocore

Antonio Postigo

Chief Scientific Officer,

Stratosvir

Aswin Doekhie

Chief Technology Officer,

Ensilicated Technologies Ltd

Baldur Sveinbjørnsson

Chief Scientific Officer,

Lytix Biopharma

Bassam Hallis

Deputy Director of Research and Evaluation,

UK Health Security Agency

Benjamin Lindner

Data Scientist,

Boehringer Ingelheim RCV GmbH & Co KG

Berit Olsen Krogh

Senior Research Fellow,

Lundbeck

Bernard Maillere

Head of Laboratory,

CEA

Bjorn Onfelt

Professor of Applied Physics,

Royal Institute of Technology

Brian Schanen

Head of Biomarker Research for the mRNA Center of Excellence,

Sanofi

Caleb McClain

Chief Executive Officer,

ANUNA (AI+BIO)

Callum Scott

Head of Development,

Scancell Ltd

Carla Vinals

Vice President, Global Regulatory Product Strategy,

Moderna Therapeutics

Carol Sze Ki Leung

Principal Investigator ,

Ludwig Institute, Oxford University

Charlotte Vernhes

Scientific and Medical Affairs Director,

Vaccines Europe

Christian Garde

Scientific Director, Bioinformatics,

Evaxion A/S

Christopher Scott

Professor,

Queen's University Belfast

Dan Hardy

Chief Executive Officer,

Microsol

Daniel Fonseca

Senior Research Scientist I ‑ Experimental Immunology,

Immunocore

Daniel Larocque

Innovation Leader,

Sanofi

Daniel Sejer Pedersen

Chemical Development Specialist,

Novo Nordisk A/S

David Brockwell

Professor,

University of Leeds

David Craik

Professor,

The University of Queensland

David Pejoski

Co-founder, Co-Chief Executive Officer, Chief Operating Officer, & Board Member,

Adoram Therapeutics

David Wraith

Professor,

UNIVERSITY OF BIRMINGHAM

Denise Steckel

Industry Clinical Collaborations Lead,

Genentech

Deniz Eris

Principal Scientist,

Novartis

Ed Tate

Professor,

Imperial College London

Eef Dirksen

Director Analytical Development & Quality Control,

Byondis B.V.

Elisa Marelli

Research Scientist,

Scancell

Elizabeth Boulter

Senior Scientist,

AstraZeneca

Erik Vernet

VP,

Novo Nordisk

Ernst Weber

Head of Molecular Design & Engineering & Bayer Science Fellow,

Bayer AG

Etienne Matous

Sr. Principal Scientist - Antibody Discovery and Engineering – Head of Lead Optimization,

IGI - Ichnos - Glenmark Innovation

Fazel Shabanpoor

Lab Head Peptide And Oligonucleotide Therapeutics,

The Florey Institute of Neuroscience and Mental Health

Felix Schumacher

Program Leader Targeted Therapeutics,

Roche

Francisca Wollerton

Senior Director,

AstraZeneca

Gabriel Wong

Senior Medical Director,

AstraZeneca

Georgios Skretas

Director,

Biomedical Sciences Research Center "Alexander Fleming"

Giulio Russo

Senior Scientist,

Merus

Hans Melo

CEO,

Menten AI, Inc

Hans van der Vliet

Professor, Medical Oncologist,

LAVA Therapeutics

Helen Bright

Chief Scientific Officer,

Centauri Therapeutics

Helene Kaplon

Translational Scientist,

Servier

Henry Maun

Staff Scientist,

Genentech

Hester Van Zeeburg

Project Manager Immune & Disease Monitoring,

Mendus AB

Ian Hamley

Professor of Physical Chemistry,

University of Reading

Ijeoma Uchegbu

Professor of Pharmaceutical Nanoscience,

University College London

Immanuel Lerner

Chief Executive Officer,

Pepticom

Isabelle Sermadiras

Associate Principal Scientist,

AstraZeneca

Itishri Sahu

Program Lead Therapeutics,

Ziphius Vaccines

Iulia Oita

CMC Manager,

Ziphius Vaccines

Janos Tibor Kodra

Principal Scientist,

Novo Nordisk

Jean Ge

Patent Attorney,

Wolf Greenfield

Jennifer Percival-Alwyn

Scientific Leader,

GSK

John Maher

Chief Scientific Officer,

Leucid Bio

Jonathan Kwok

Chief Executive Officer,

Infinitopes

Joost Uitdehaag

Head of Biology,

Crossfire Oncology B.V.

Jörg Wischhusen

Professor,

University Hospital Würzburg

Jutta Eichler

Professor Medicinal Chemistry,

University of Erlangen-Nurnberg

Karen Silence

Vice President,

Argenx BVBA

Kate Smith

UK Head Protein And Cell Sciences,

GlaxoSmithKline

Ken Chow

Health Tech Counsel,

Flanders Investment & Trade, Belgium Embassy (London)

Kevin Maskell

Research Director,

Bioarchitech

Knud Jørgen Jensen

Professor,

Copenhagen University

Kuda Muchandibaya

Lecturer for Supply Chain Management & Logistics,

Rhine-Waal University of Applied Sciences

Laura Collins

Director Bioinformatics,

Immunocore

Laura Starkie

Director,

UCB

Leonardo De Maria

Principal Scientist,

AstraZeneca

Louis Diorazio

Senior Principal Scientist, New Modalities,

AstraZeneca

Lucia Ferrazzano

Junior Assistant Professor,

University of Bologna

Lukas Pekar

Lab Head,

Merck

Mads Hald Andersen

Professor,

National Centre For Cancer Immune Therapy (CCIT-dk)

Mani Mudaliar

Director, Quantitative Biomarkers,

Recursion

Marc Vendrell Escobar

Professor of Translational Chemistry,

University of Edinburgh

Maria Fawaz

Associate Principal Scientist,

MSD

Marie McAvoy

Chief Scientific Officer,

Nanosyrinx

Marina Fedorova

Scientific Investigator,

GSK

Mark Eccleston

CEO,

Valirx

Markus Templin

Head Cellular And Molecular Biology,

Nmi Natural And Medical Sciences Institute

Martina Ochs

Project Leader,

CEPI

Mathieu Cinier

Scientific Director,

Affilogic

Matthew Burrell

Associate Director,

AstraZeneca

Mattias Malm

Senior Scientist,

Ferring Pharmaceuticals

Micaela Graglia

Analytical Chemist, Molecular Design,

Silence Therapeutics

Michael Delaney

Senior Principal Scientist,

Novo Nordisk

Mihaela Bozic

Scientist,

T-Therapeutics Ltd

Mikhail Kuravskiy

Proncipal Scientist,

UCB

Nathan Alves

Research Director,

Indiana University School of Medicine

Nesrine Chakroun

Associate Director,

Merus NV

Nicola Ferrari

Director,

AstraZeneca

Norbert Furtmann

Head of AI Innovation NANOBODY® Platform,

Sanofi

Obinna C Ubah

Principal Scientist/Programme Lead,

Elasmogen Ltd

Owen Vickery

Associate Principal Scientist,

AstraZeneca

Patricia Alves

Head of the Sanofi Satellite Lab & Coordinator of Analytical Services Unit and Mass Spectrometry Unit,

Instituto de Biologia Experimental e Tecnológica

Paul Wassmann

Senior Principal Scientist,

Novartis AG

Pawel Stocki

Vice President,

Ossianix

Peter Sondermann

Chief Executive Officer,

Tacalyx GmbH Privacy Policy Imprint

Prasun Chakraborty

CEO and Founder,

Genevation LTD

Raj Mehta

Chief Executive Officer,

Adendra Therapeutics

Raymond Tesi

President & Chief Executive Officer,

InMune Bio

Reeta Daswani

Senior Scientist II,

Sixfold Biosciences

Rita Martello

Scientific Director, NBE DMPK Lead,

Merck KGaA

Robert Andrews

Partner,

Mewburn Ellis LLP

Rodrigo Abreu

Principal Scientist,

LifeArc

Russell LaMontagne

Chief Executive Officer,

BITT

Sagar Kathuria

Sr. Scientist, Protein Engineering I,

Sanofi

Sandra Tremmel

Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,

Roche

Sandrien Janssens

CMC Director,

Mosanna Therapeutics

Santiago Parpal

Principal Scientist,

Sprint Bioscience

Sarah Hindson

Senior Scientist,

GSK

Sarah Stuart

High Throughput Characterisation Team Leader,

GSK

Saurabh Sen

Associate Director, Cell Line Development, Mammalian Platform Biologics,

Sanofi

Sebastian Sten

Associate Principal Scientist,

AstraZeneca

Sevim Ozgur Bruderle

Lab Head,

Sanofi

Shao-An Xue

Honorary Professor,

University College London

Silvia Crescioli

Business Intelligence Creator,

The Antibody Society

Simon Hufton

Section Head Molecular Immunology, Division of Biotherapeutics,

MHRA

Simone Friedrich

Director Antibody Discovery & Development,

iOmx Therapeutics

Sonia Macia

Chief Medical Officer,

Aromics Therapeutics

Sonja Merkas

Founder, Creator & Doer,

Livinovea

Sophia Karagiannis

Professor of Translational Cancer Immunology and Immunotherapy,

King's College London

Sritama Bose

Associate Director of Chemistry,

Nucleic Acid Therapy Accelerator, Medical Research Council (UKRI)

Stefan Zielonka

Senior Director, Global Head of Antibody Discovery & Protein Engineering,

Merck KGaA

Stephen Miller

Principal Scientist,

Genentech

steve Hood

Director Oligo ADME Strategy,

GSK

Steven Schmitt

Co-Founder & Chief Executive Officer,

Myria Biosciences

Stine Friis Thorsen

Director Clinical Development,

Evaxion Biotech

Sue Charlton

Head of Clinical Evaluation,

UK Health Security Agency

Talip Ucar

Senior Director,

AstraZeneca

Tatyana Ponomaryov

Principal Scientist,

Plasticell

Thomas Kraft

Principal Scientist,

Roche

Thomas Powell

Senior Scientist,

Immunocore

Timothy Hickling

Immunogenicity Expert Scientist,

Roche

Tomasz Witkos

Associate Director,

AstraZeneca

Toria Legh-Land

Modelling Lead,

Microsol

Trevor Smith

Vice President,

Inovio

Ulrike Rieder

Scientific Lead & Project Leader Oligonucleotides / New Modalities,

Novartis

Vaios Karanikas

Biomarker Portfolio Leader,

Roche

Vik Reebye

Head of Academic Partnerships ,

MiNA Therapeutics Ltd

Vincent Dewar

Head of Immunoassay,

GSK

Vincenzo de Filippis

Associate Professor Biochemistry,

University of Padova

Walter Cabri

Professor,

University of Bologna

Wen-Hsuan Chang

Associate Vice President, Discovery and Early Development,

AcuraStem

Will Nesbit

Senior Director - Process Chemistry & CMC,

Bicycle Therapeutics

Wolfgang Koch

Senior Scientist,

F-star Therapeutics Inc

Yann Abraham

Associate Director AI for Single Cell,

Johnson & Johnson Innovative Medicine

Yiping Wu

Senior Scientist,

AstraZeneca

Zahra Rattray

Reader,

University of Strathclyde

Zinaida Dedeic

Senior Scientist,

University of Oxford

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Find Out More

Interested in Sponsoring NextGen Biomed?

In-Person Services Digital Marketing Services

The 1-2-1s are the best thing about Oxford Global events, well organised and good number of relevant contacts. Good high level contacts from big companies.

Advanced Therapies Specialist Team Leader,
Genscript

Biologics 2024 has been one of the best events I have attended so far in my career.

Territorial Sales Manager UK,
ACROBiosystems Co., Ltd.

Impressed by the effort to bring people together.

Business Development Director,

Bioassay

Nice set-up, with good support for exhibitors

Director of Client Relations,

ImmunoPrecise

The start-up zone provides a unique opportunity for you to exhibit, network, and pitch to our global audience of pharma, biotech, and investment professionals.

It's designed for start-ups from across the biologics space, working on cutting-edge therapies, innovative platform technologies, products, and solutions and is an ideal platform to share your business plans and promote your science.

There are two options, based on the type of your organisation with prices starting from £1,500 (+VAT) for companies with own therapeutic research pipeline and registration from £3,500 (+VAT) available for companies offering solutions, services or platform technologies.

For further information and to get started submit the application form below.

The NextGen Biomed Best Poster Presentation Competition & Award includes the best poster presentation award and is intended to honour an outstanding individual performance for a scientific work by either an early career or established scientist, including PhD student and PostDocs.

Please submit your poster presentation by no later than 13^th January 2025 in the below category:

Protein/Antibody Engineering
Bioanalysis & Characterisation
Next Generation Biotherapeutics
Peptides Chemistry & Therapeutics
Oligonucleotides Chemistry & Therapeutics
Sustainable Chemistry & Manufacturing

- Open to all scientists, including students (PhD), PostDocs, and established researchers representing pharma & biotech companies and/or academic institutions
- Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
- ONLY ONE submission per person will be accepted. If authors submit multiple abstracts for consideration for the competition, only one abstract will be taken into consideration

Applicants must follow the procedure as follows:

Register and submit an abstract by 13th January 2025 using the registration link to the right on this page. Please ensure you add the poster display option on the registration page to secure your admission into the Best Poster Competition & Award

Once registered you will be provided with the online abstract submission form

Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.)

The winner with the highest scores will be announced at the Morning Networking Break on Day 3 of the event

The poster presentations will be evaluated by everyone attending the event on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). Attendees will be allowed to cast one vote by selecting their favourite work in the poster area. All votes will be counted at the end of Day 2 at 5pm and results will be announced during the morning networking break on Day 3. .

The winner receiving the highest scores will be announced on Day 3 and will be given a trophy as well as £600 contribution towards travel & accommodation costs to attend the 2026 NextGen Biomed event. Oxford Global will also provide winners with PLUS Pass – 12 months access to our digital content platform providing access to on-demand presentations, exclusive reports and highlights.